S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Cytori Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.04 (-2.26 %)
(As of 10/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume205,284 shs
Average Volume915,302 shs
Market Capitalization$38.34 million
P/E RatioN/A
Dividend YieldN/A

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cytori Therapeutics logo

About Cytori Therapeutics

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.


Phase 3
February 5, 2021 |  benzinga.com
August 19, 2020 |  markets.businessinsider.com
News for Cytori Therapeutics Inc Registered Shs
August 17, 2020 |  markets.businessinsider.com
Plus Therapeutics Inc
August 14, 2020 |  reuters.com
Cytori Therapeutics (CYTX) - Options Chain
March 25, 2020 |  www.fool.com
Plus Therapeutics to reverse split 1:50
July 29, 2019 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.67 million
Book Value
$0.35 per share


Net Income
$-12.63 million
Net Margins




Market Cap
$38.34 million
Next Earnings Date


Overall MarketRank

0.99 out of 5 stars

Medical Sector

1239th out of 1,358 stocks

Surgical & Medical Instruments Industry

117th out of 124 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What stocks does MarketBeat like better than Cytori Therapeutics?

Wall Street analysts have given Cytori Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytori Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) announced its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.
View Cytori Therapeutics' earnings history

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the following people:
  • Marc H. Hedrick, President, Chief Executive Officer & Director
  • Gary S. Titus, Chief Financial Officer
  • Mark T. Marino, Chief Medical Officer & Senior Vice President
  • John K. Fraser, Chief Scientist
  • Russ Havranek, VP-Global Marketing & Business Development

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $1.73.

How much money does Cytori Therapeutics make?

Cytori Therapeutics has a market capitalization of $38.34 million and generates $3.67 million in revenue each year.

How many employees does Cytori Therapeutics have?

Cytori Therapeutics employs 37 workers across the globe.

What is Cytori Therapeutics' official website?

The official website for Cytori Therapeutics is www.cytori.com.

Where are Cytori Therapeutics' headquarters?

Cytori Therapeutics is headquartered at 3020 CALLAN ROAD, SAN DIEGO CA, 92121.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected].

This page was last updated on 10/23/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.